Get the Stockscreener App
2.45
1.24%
0.03
Pre-market:
2.60
0.15
+6.12%
Alaunos Therapeutics Inc stock is traded at $2.45, with a volume of 21,955.
It is up +1.24% in the last 24 hours and down -11.23% over the past month.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
See More
Previous Close:
$2.42
Open:
$2.52
24h Volume:
21,955
Relative Volume:
1.46
Market Cap:
$5.98M
Revenue:
$5,000
Net Income/Loss:
$-4.18M
P/E Ratio:
-1.0908
EPS:
-2.2461
Net Cash Flow:
$-2.97M
1W Performance:
-2.00%
1M Performance:
-11.23%
6M Performance:
-27.08%
1Y Performance:
-7.89%
1-Day Range:
$2.30
$2.59
1-Week Range:
$2.30
$2.59
52-Week Range:
$1.67
$6.20
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Name
Alaunos Therapeutics Inc
Sector
Industry
Phone
(346) 355-4099
Address
501 E LAS OLAS BLVD, FORT LAUDERDALE
Compare TCRT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
2.45 | 5.91M | 5,000 | -4.18M | -2.97M | -2.2461 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Stock (TCRT) Latest News
Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results - Stocktwits
Alaunos Reports Positive Preclinical Metabolic Data for ALN1003 - TipRanks
Alaunos reports preclinical data for obesity drug candidate ALN1003 - Investing.com UK
Alaunos Therapeutics Reports Positive Preclinical Results for ALN1003 in Addressing Metabolic Disease Markers - Quiver Quantitative
ALN1003 obesity data and cash runway update from Alaunos (NASDAQ: TCRT) - Stock Titan
TCRT Q4 2023 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Reports No RevenueGuidance Update - Newser
Alaunos Therapeutics (TCRT) Q4 2023 Earnings Fall Short: EPS $-4.90 Misses MarkBuyback Announcement Report - Newser
Alaunos Therapeutics (TCRT) Reveals Promising Preclinical Data f - GuruFocus
Alaunos Therapeutics, Inc.Common Stock (Nasdaq:TCRT) Stock Quote - FinancialContent
Alaunos Therapeutics Announces Promising Preclinical Results for ALN1003 in Metabolic Syndrome and Obesity Models - Minichart
Alaunos reports preclinical data for obesity drug candidate - Investing.com UK
Alaunos reports preclinical data for obesity drug candidate By Investing.com - Investing.com Nigeria
Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models - The Manila Times
Alaunos (Nasdaq: TCRT) shows ALN1003 obesity data, reports $0.354M cash - Stock Titan
Experimental obesity pill shows liver and insulin-resistance effects in mice - Stock Titan
TCRT Alaunos Therapeutics reports widening losses as revenue plummets 50 shares fall 326Social Buy Zones - newser.com
Ziopharm: Q1 Earnings Snapshot - marketscreener.com
Alaunos Therapeutics, Inc. 1Q 2026: Revenue $0K, EPS $(0.59) — 10-Q Summary - TradingView
Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Alaunos Therapeutics (NASDAQ: TCRT) Q1 2026 loss, cash runway and Nasdaq equity deficiency - Stock Titan
TCRT Should I Buy - Intellectia AI
Headline News about Alaunos Therapeutics, Inc.Common Stock - FinancialContent
MSN Money - MSN
TCRT Alaunos Therapeutics reports widening losses as revenue plummets 50%, shares fall 3.26%.Value Pick - newser.com
Alaunos Therapeutics (TCRT) Eps Diluted (TTM) - Zacks Investment Research
TCRT Stock Price, Quote & Chart | ALAUNOS THERAPEUTICS INC (NASDAQ:TCRT) - ChartMill
Why Alaunos Therapeutics (TCRT) looks solid from every angle (Smart Money Flows) 2026-05-06Wall Street Picks - newser.com
Former Alaunos legal chief joins Valion Bio for FDA, CDMO push - Stock Titan
TCRT Alaunos Therapeutics posts wider Q4 2023 loss than analyst estimates, with shares slipping 0.39 percent in today’s trading.Social Trading Insights - newser.com
Alaunos Therapeutics (TCRT) director awarded 6,515 shares at $2.59 - Stock Titan
Alaunos Therapeutics (TCRT) director receives 6,274-share stock grant in lieu of fees - Stock Titan
Director at Alaunos (TCRT) receives 6,032-share stock award - Stock Titan
Alaunos Therapeutics 2025 Proxy Statement – Board Members, Executive Compensation, and Corporate Governance Overview - Minichart
Alaunos Therapeutics (NASDAQ: TCRT) details board, pay and ownership in 10-K/A - Stock Titan
Alaunos Therapeutics (TCRT) Moat Analysis | Q4 2023: EPS Misses EstimatesStability Report - Xã Châu Thành
Alaunos Therapeutics receives Nasdaq notice for non-compliance with equity rule - Investing.com
Alaunos Therapeutics Faces Nasdaq Non-Compliance, Delisting Risk - TipRanks
Alaunos Therapeutics Inc Stock (TCRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):